Inovio Pharmaceuticals, Inc. · NASDAQ:INO
Inovio Pharmaceuticals — Corporate Update (November 2026)
25 slides from Inovio Pharmaceuticals's corporate update, Nov 2, 2026
Slide 1: FDA Accelerated Approval of VOCERYQ Investor Call
FDA Accelerated Approval of VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) Investor Call November 2, 2026
Slide 2: Agenda for VOCERYQ Approval Call
Agenda for VOCERYQ Approval Call Introduction Jacqueline Shea, PhD, President & Chief Executive Officer Prescribing Information and Label Details Michael Sumner, MBBS, MBA, Chief Medical Officer Commercial Launch Plans Steve Egge, MBA, Chief Commercial Officer VOCERYQ and Platform Potential Jacqueli
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation includes statements that are, or may be deemed, “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended. All statements, other than statements of historical facts, included in this presentation regarding o
Slide 4: A Pivotal Moment for RRP Patients and INOVIO
A Pivotal Moment for RRP Patients and INOVIO VOCERYQ Reduces the First product New treatment need for surgery for INOVIO, option with broad by targeting the major milestone indication for underlying viral for DNA medicine adults with RRP cause of RRP 4
Slide 5: Prescribing Information and Label Details
Prescribing Information and Label Details
Slide 6: VOCERYQ Now Approved
VOCERYQ Now Approved Formerly known as INO-3107 Approved to reduce the frequency of surgery in adults with RRP This indication is approved under accelerated approval based on reduction in the frequency of surgical papilloma excisions. Continued approval for this indication may be contingent upon ver
Slide 7: Recurrent Respiratory Papillomatosis (RRP)
Recurrent Respiratory Papillomatosis (RRP) Rare disease characterized by small, wart-like growths (papillomas) in the respiratory tract Repeated surgery is standard of care – every surgery entails significant risk and cost • Potential for irreversible damage to vocal cords • Impact on quality of lif
Slide 8: Multi-Center Clinical Study at 8 Clinical Sites
Multi-Center Clinical Study at 8 Clinical Sites RRP-001 PHASE 1/2 OPEN-LABEL STUDY RRP-002 DURABILITY EXTENSION / FOLLOW-UP Baseline: DAY 0 52 WEEKS 104 WEEKS 156 WEEKS Patients Enrolled 4 Doses of INO-3107 Completed Study Consented to Follow Up Median Completed Follow Up Follow Up N=32 N=32 N=28 N=
Slide 9: Efficacy Endpoint for Approval
Efficacy Endpoint for Approval Based on Reduction in Surgery in 12 Months Following Dosing Completion Analysis ends Week 0 3 6 9 Week 61 DOSING 4 doses total Efficacy Analysis Period*: Weeks 9-61 (N=26) (≥3 surgeries in the 12 months prior to treatment) *Includes data from weeks 9-52 from RRP-001 an
Slide 10: Patient-Centric Treatment Regimen
Patient-Centric Treatment Regimen Does not require scoping and surgical removal of visible papilloma during dosing window Straightforward storage, requiring only standard refrigeration with a 3-year shelf life Flexibility in the administration location, including doctor’s office 10
Slide 11: Simple Administration with CELLECTRA
Simple Administration with CELLECTRA® Prepare Device & Patient Select injection site in the thickest part of the deltoid muscle in the upper arm Deliver VOCERYQ CELLECTRA® injects VOCERYQ , then provides short electrical pulses to briefly create reversible pores in the cell membrane to allow VOCERYQ
Slide 12: Key Safety Results - Most Adverse Reactions Grade 1 or 2
Key Safety Results - Most Adverse Reactions Grade 1 or 2 Adverse Reactions Occurring in > 5% of Patients in Study RRP-001 (N=32) Adverse Reactions RRP (N=32) n (%) Injection site reaction 11 (34%) Headache 6 (19%) Fatigue 5 (16%) Hypertension 4 (13%) Nausea 2 (6%) Dizziness 2 (6%) Other clinically s
Slide 13: FDA Alignment on Future Confirmatory Study
FDA Alignment on Future Confirmatory Study Proposed protocol design due to FDA by end of 2026; expected to be finalized by mid-2027 Current general protocol design components: • 50+ adult and pediatric patients with RRP who had 3+ surgeries in 12 months prior to treatment with VOCERYQ TM • Evaluate
Slide 14: Commercial Launch Plans
Commercial Launch Plans
Slide 15: Large Addressable Patient Population with High Unmet Need
Large Addressable Patient Population with High Unmet Need 25,000+ prevalent population of patients with RRP based on ongoing claims data analysis A significant market opportunity • Immunotherapy, including VOCERYQTM, is recommended as first-line therapy for RRP* VOCERYQTM has the potential to become
Slide 16: Patient Journey – Every Surgery Matters
Patient Journey – Every Surgery Matters 4 doses over 9 weeks Diagnosis Decision to treat (no scoping or surgery (surgery and/or biopsy) with VOCERYQ required during dosing) KOL recommendation: Patient undergoes start immunotherapy initial papilloma as soon as possible* removal VOCERYQ can reduce the
Slide 17: Key Priorities for a Successful Launch
Key Priorities for a Successful Launch Establish Drive awareness Provide seamless patient broad access & adoption & customer support Policies in place for Engage targeted Through the insurers that cover laryngologists and VOCERYQ Support 80% of patients staff to educate on Program make access within
Slide 18: Targeting and Field Deployment
Targeting and Field Deployment Driving rapid awareness, adoption and patient access Highly concentrated market* ~400 Laryngologists Field footprint** will cover treat the vast majority of RRP patients ~90% of RRP patient potential ~80% of patients • 20 territories managed by experienced receive care
Slide 19: Foundations for Long-term Commercial Success
Foundations for Long-term Commercial Success Established infrastructure to enable a successful launch Potential for commercial success • Manufacturing network with current • Strength of clinical data inventory and capacity expected to support • Broad adult indication launch at least through 2027 • S
Slide 20: VOCERYQ and Platform Potential
VOCERYQ and Platform Potential
Slide 21: VOCERYQ Program Expansion
VOCERYQTM Program Expansion Additional Expansion in treatment international strategies markets 21
Slide 22: Advancing Our Pipeline Strategy
Advancing Our Pipeline Strategy NEAR TERM MID TERM NEXT GEN Commercialization Advancing Innovating of VOCERYQTM Diversified NextGen Clinical Pipeline DNA Medicines 22
Slide 23: Delivering on the Promise of DNA Medicine
Delivering on the Promise of DNA Medicine Approval of first product VOCERYQTM and transition to commercial stage company Landmark moment for INOVIO and DNA medicine platform Compelling efficacy, tolerability & patient-centric treatment regimen = potential to become preferred first-line treatment opt
Slide 24: Q&A
Q&A
Slide 25: Thank you.
Thank you. Investors: Media: Peter Vozzo Josephine Galatioto Peter.Vozzo@icrhealthcare.com inoviopr@icrhealthcare.com
INOVIO Pharmaceuticals — Corporate Update (November 2026) on 6ix